Dealing with the spiralling price of medicines: issues and solutions.

about

Fast-tracking of new drugs: getting the balance right

P2860

Q58805903-E574DAA6-2FC1-495C-AE9C-0FAD430AAA57

P2860

Dealing with the spiralling price of medicines: issues and solutions.

Item

http://www.wikidata.org/entity/Q50080930

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dealing with the spiralling price of medicines: issues and solutions.

@en

Dealing with the spiralling price of medicines: issues and solutions.

@nl

type

Item

label

Dealing with the spiralling price of medicines: issues and solutions.

@en

Dealing with the spiralling price of medicines: issues and solutions.

@nl

prefLabel

Dealing with the spiralling price of medicines: issues and solutions.

@en

Dealing with the spiralling price of medicines: issues and solutions.

@nl

P1476

Dealing with the spiralling price of medicines: issues and solutions.

@en

P2093

Chun K K Ma

http://www.w3.org/2001/XMLSchema#string

David D F Ma

http://www.w3.org/2001/XMLSchema#string

Mark Danta

http://www.w3.org/2001/XMLSchema#string

Richard Day

http://www.w3.org/2001/XMLSchema#string

P2860

Patented drug extension strategies on healthcare spending: a cost-evaluation analysis

A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

Cancer drugs in the United States: Justum Pretium--the just price

Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

P304

16-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.13652

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29068529

http://www.w3.org/2001/XMLSchema#string

Dealing with the spiralling price of medicines: issues and solutions.

about

P2860

P2860

Dealing with the spiralling price of medicines: issues and solutions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698